/ /

dry eye

Can cannabis succeed where other compounds have failedUse of a novel semi-fluorinated alkane drug delivery technology as a vehicle to deliver cannabinoids to the ocular surface reached target tissues without systemic side effects in preclinical studies.
Opportunities and challenges in the world of ophthalmology in 2018As another year comes to an end, five members of Ophthalmology Times Europe’s Editorial Advisory Board reflect and share their perspectives on the exciting opportunities that lie ahead for ophthalmologists in 2018, whilst also considering the potential challenges.
Tear osmolarity: Dry eye's 'vital sign'Hyperosmolarity emerges as key mechanism in TFOS DEWS II pathophysiology report
Biologic products increase dry eye optionsMany new diagnostic tools are available for dry eye and ocular surface disease (OSD). Treatments for dry eye and OSD have mixed results, however, said Bennie H. Jeng, MD.
TFOS DEWS II report introduces new patient classification schemeJ. Daniel Nelson, MD, chair of The Tear Film and Ocular Surface Society Dry Eye Workshop II, highlights a new scheme for patient classification.
Four ocular surface health questions to consider before cataract surgeryA thorough investigation of ocular surface health and initiation of any necessary treatment is the first step toward successful cataract surgery.
New metrics, new therapies for dry eyeRecently, there has been a greater interest in metrics focused upon the impact of dry eye disease on everyday activities such as reading, driving, or use of various visual display devices. These efforts provide a “real-life” assessment of how dry eye disease impacts vision-related activities.
Intranasal neurostimulation yields positive results for dry eye diseaseThe first portable, external neurostimulator to be approved in eye care stimulates endogenous tear production without physical irritation. The device can dramatically reduce symptoms and may enable patients to stop use of some or all tear substitutes or medications, noted John Sheppard, MD, MMSc.
Testing at point of care for improved patient satisfaction, re-treatment ratesAfter spending a few months testing for dry eye and treating the tear film before doing preoperative measurements, the re-treatment rate dropped from 11% to 3%.
Yet another new revolution in ocular surface imagingDuring the past two decades, an incredible number of imaging technologies have been developed for eye diseases, both for diagnosis and follow-up.